Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
15 Janvier 2025 - 1:00PM
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on
patients treated by ear, nose and throat (ENT) and allergy
specialists, today announced preliminary unaudited XHANCE®
(fluticasone propionate) net product revenue of $22.4 million for
the three months ended December 31, 2024.
“Our preliminary unaudited fourth quarter net product revenue of
$22.4 million is in line with our prior guidance and demonstrates a
sustained growth in XHANCE prescriptions through the fourth quarter
of 2024,” stated CEO Ramy Mahmoud. “For prescriptions, we estimate
an approximately 20% sequential growth rate from third quarter to
fourth quarter 2024, which is encouraging as we continue to focus
on commercial execution and continued growth in the year ahead. We
look forward to reporting full financial results for fourth quarter
2024 and corporate updates in March.”
The fourth quarter net product revenue and prescription growth
rate included in this press release are preliminary results based
on the information available to the Company at this time. Actual
results may vary materially from the preliminary results presented
in this press release due to the completion of the Company’s
financial closing procedures, review adjustments and other
developments or information that may arise between now and the time
the Company’s financial results for fourth quarter 2024 are
finalized. Additionally, the preliminary results have not been
audited or reviewed by the Company’s independent registered public
accounting firm. Accordingly, you should not place undue reliance
on this preliminary data. The Company expects to report full
financial results for the fourth quarter of 2024 and corporate
updates in March.
About OptinoseOptinose is a
specialty pharmaceutical company focused on serving the needs of
patients cared for by ear, nose and throat (ENT) and allergy
specialists. To learn more, please visit www.optinose.com or
follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements that are not historical facts are hereby
identified as forward-looking statements for this purpose and
include, among others, statements relating to: preliminary
unaudited XHANCE net revenue and prescription growth for the three
months ended December 31, 2024; sustained growth in XHANCE
prescriptions through the fourth quarter of 2024; the Company’s
focus on commercial execution and continued growth in 2025; the
Company’s expectation to report full financial results for fourth
quarter 2024 and corporate updates in March; and other statements
regarding the Company's future operations, financial performance,
financial position, prospects, objectives, strategies and other
future events. Forward-looking statements are based upon
management’s current expectations and assumptions and are subject
to a number of risks, uncertainties and other factors that could
cause actual results and events to differ materially and adversely
from those indicated by such forward-looking statements including,
among others: the potential for the preliminary unaudited XHANCE
net product revenue for the three months ended December 31, 2024 to
change in connection with the finalization of the Company’s
financial results for such period and review/audit by the Company’s
independent registered public accounting firm, and the potential
for preliminary estimated XHANCE prescription growth for the three
months ended December 31, 2024 to change in connection with
finalization of third-party inventory and prescription data as well
as data from the Company’s hub and PPN partners, as well as, in
each case, other developments or information that may arise between
now and the time the Company’s financial results for fourth quarter
2024 are finalized; physician and patient acceptance of XHANCE for
its new indication; the Company’s ability to maintain adequate
third-party reimbursement for XHANCE (including its new
indication); the prevalence of chronic sinusitis and market
opportunities for XHANCE may be smaller than expected; the
Company’s ability to efficiently generate XHANCE prescriptions and
net revenues; and the risks, uncertainties and other factors
discussed under the caption "Item 1A. Risk Factors" and elsewhere
in the Company’s most recent Form 10-K and Form 10-Q filings with
the Securities and Exchange Commission - which are available at
www.sec.gov. As a result, you are cautioned not to place undue
reliance on any forward-looking statements. Any forward-looking
statements made in this press release speak only as of the date of
this press release (January 15, 2025), and the Company undertakes
no obligation to update such forward-looking statements, whether as
a result of new information, future developments or otherwise.
Optinose Investor Contact Jonathan
Neelyjonathan.neely@optinose.com 267.521.0531
OptiNose (NASDAQ:OPTN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
OptiNose (NASDAQ:OPTN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025